Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review.

ingentiumby ingentium

In Clinical Literature.

Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review.

Publication date: Jun 29, 2025

This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT). Our findings demonstrate that the combination of ASCT and CAR-T for sCNSL may be feasible, even for SARS-CoV-2-positive immunocompromised lymphoma patients.

Open Access PDF

Concepts Keywords
Car COVID-19
Cd19
Covid
Immunocompromised
Old

Semantics

Type Source Name
disease IDO cell
disease MESH lymphoma
disease MESH COVID-19
disease MESH infection
pathway REACTOME Reproduction
disease MESH diffuse large B cell lymphoma
disease MESH relapse
disease MESH malignancies
disease MESH syndrome
disease IDO production
disease MESH hematological malignancies
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease IDO history
disease MESH genetic disease
disease IDO blood
drug DRUGBANK Rituximab
drug DRUGBANK Vindesine
drug DRUGBANK Ifosfamide
drug DRUGBANK Doxorubicin
drug DRUGBANK Prednisone
drug DRUGBANK Framycetin
drug DRUGBANK Gemcitabine
drug DRUGBANK Oxaliplatin
disease MESH edema
pathway REACTOME Glucose metabolism
drug DRUGBANK Temozolomide
drug DRUGBANK Thiotepa
drug DRUGBANK Etoposide
drug DRUGBANK Cytarabine
drug DRUGBANK Melphalan
disease MESH agranulocytosis
drug DRUGBANK Caspofungin
drug DRUGBANK Ritonavir
drug DRUGBANK Levetiracetam
drug DRUGBANK Ursodeoxycholic acid
drug DRUGBANK Alprostadil
drug DRUGBANK Sulfamethazine
drug DRUGBANK Thymidine monophosphate
drug DRUGBANK Acyclovir
disease MESH aplasia
drug DRUGBANK Methotrexate
drug DRUGBANK Lenalidomide
drug DRUGBANK Pomalidomide
disease MESH hypogammaglobulinemia
disease IDO nucleic acid
disease MESH viral load
disease MESH viral shedding
disease IDO process
disease IDO intervention
disease IDO immunosuppression
disease MESH nosocomial infection
disease MESH treatment delay
drug DRUGBANK Ibrutinib
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH B cell lymphoma
disease MESH Burkitt lymphoma
disease MESH leukemia
disease MESH viral infection
drug DRUGBANK Decitabine
disease MESH death
disease MESH non Hodgkin lymphoma

Original Article

(Visited 9 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *